Purpose: Though histological grade is known to have a major prognostic impact in metastatic mucinous appendiceal adenocarcinomas, the prognostic impact of grade in localized disease, and the validity of the American Joint Committee on Cancer AJCC Staging Manual 7th edition's decision to combine moderately and poorly differentiated mucinous adenocarcinomas into a single mucinous high-grade category, is not known. Methods: Patients with adenocarcinoma of the appendix diagnosed between 1988 and 2007 were identified from the SEER database. Cancerspecific survival (CSS) stratified by histological subtype, stage, and grade was calculated, and Cox proportional hazards regression analyses were performed. Results: We analyzed a total of 2469 appendiceal adenocarcinomas, of which 1375 had mucinous histology and 860 had nonmucinous histology. Though overall CSS was similar for mucinous and nonmucinous subtypes, differences in stage distribution and stage-stratified CSS were seen. Female sex, stage IV disease, and well-differentiated histology were more common for mucinous adenocarcinomas. Histological grade had a strong prognostic impact, especially in patients with stage IV mucinous adenocarcinoma. The adjusted hazard ratios for stage IV moderately and poorly differentiated histological grade were 1.63 [95% confidence interval (CI): 1.14-2.34] and 4.94 (95% CI: 3.32-7.35) for mucinous histology, in comparison with 1.44 (95% CI: 0.82-2.52) and 1.90 (95% CI: 0.95-3.80) for nonmucinous histology, respectively.
M alignancy of the appendix is rare, with an age-adjusted incidence of 0.12 cases per 1,000,000 person-years. 1 Often the diagnosis is unexpected, and it is found in approximately 1% of all appendectomy specimens. 2, 3 Adenocarcinomas represent approximately two thirds of these cases and can be subdivided into mucinous, nonmucinous (or colonic-type), and signet-ring cell histological subtypes. 1 Although signet-ring cell adenocarcinomas are known to have a worse prognosis, the prognostic impact of mucinous and nonmucinous histological subtypes has not been well studied.
Retrospective series have demonstrated both better 4-6 and worse 7, 8 prognoses in patients with mucinous as opposed to nonmucinous histological subtypes. An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry from 1973 to 1988 demonstrated no difference in all-cause survival for patients with mucinous and nonmucinous adenocarcinomas. 1 However, this finding contrasts with the distinctly different clinical behaviors that can be seen between mucinous and nonmucinous metastatic appendiceal adenocarcinomas.
In particular, metastatic well-differentiated mucinous adenocarcinomas of the appendix frequently present with the clinical syndrome of pseudomyxoma peritonei, which is characterized by the slow and progressive accumulation of mucinous ascites. For this subgroup of mucinous appendiceal adenocarcinomas, cytoreductive surgery can result in a cure, with 5-year overall survival rates of 30%-35%. 9, 10 However, the relative impact of the various histological grades in mucinous adenocarcinomas has not been well characterized, and how the histological grade may affect the outcome of nonmucinous appendiceal adenocarcinomas is unknown. In addition, no data are available regarding the prognostic impact of the histological grade on the prognosis for localized or regional appendiceal adenocarcinomas.
In the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual, appendiceal carcinomas are now classified separately from colorectal carcinomas. 11 In particular, this new edition incorporates the histological grade into the staging of stage IV disease and classifies mucinous carcinomas into 2 distinct groups: low-grade, composed of well-differentiated carcinomas, and highgrade, composed of moderately and poorly differentiated carcinomas. Though moderately and poorly differentiated mucinous adenocarcinomas are known to have worse outcomes than well-differentiated mucinous adenocarcinomas, it is not known whether the outcomes for moderate and poorly differentiated mucinous adenocarcinomas differ. 12 The purpose of this study, therefore, was to perform a population-based evaluation of outcomes of patients with appendiceal adenocarcinomas stratified by stage, grade, and histological subtype. We hypothesized that differences in survival between mucinous and
PATIENTS AND METHODS

Data Source and Case Identification
Data from the SEER Program of the National Cancer Institute, released in 2010, were utilized for this study. 13 SEER, a populationbased cancer registry, collects cancer incidence and survival data from 18 regional population-based registries that now cover approximately 26% of the US population. The SEER registry routinely collects data on patient demographics, primary tumor site, tumor morphology, disease stage at diagnosis (per the AJCC Cancer Staging Manual, since 1988), first course of treatment (radiotherapy and surgery within 4 months after cancer diagnosis), and follow-up for vital status. SEER does not collect data on chemotherapy or cytoreductive surgery, which was therefore not evaluated in this study.
Patients eligible for the study included all those with appendiceal carcinomas (ICD-O-3: C18.1) diagnosed between January 1988 and December 2007. The inclusive study dates were chosen because 1988 was the first year SEER coded data elements that would allow restaging using the AJCC Staging Manual 7th edition and 2007 was the latest available SEER release for our analysis. Data were not available to classify metastases into the 7th edition subcategories of peritoneal-only metastases (M1a) and nonperitoneal metastasis (M1b).
Appendiceal adenocarcinomas were classified into mucinous (histology types: 8470, 8480, and 8481) and nonmucinous (histology types: 8010, 8013, 8020, 8140-1, 8144, 8210-1, 8255, 8260-3, 8310, 8440, 8460, 8471-72, 8560, and 8574). Because goblet cell carcinoids (histology type 8243) demonstrated a distinctly different cancer-specific survival (CSS) than nonmucinous adenocarcinomas, they were not included in this analysis. As the signet-ring cell histological subtype (histology type 8490) had a uniquely poor prognosis, we separately evaluated it.
Exclusion criteria included an age younger than 18 years or older than 90 years, lack of histological confirmation, a survival time < 30 days, and if the incident diagnosis of appendiceal cancer was not their first and only occurrence of malignant disease. Cases were also excluded if the cancer reporting source was a nursing home, hospice, autopsy, or death certificate as these patients would not have been likely to receive cancer-directed therapy.
For comparative purposes, we applied the same criteria to all colon adenocarcinomas from the same period in the SEER registry: cecum (C18.0), ascending colon (C18.2), hepatic flexure of colon (C18.3), transverse colon (C18.4), splenic flexure of colon (C18.6), sigmoid colon (C18.7), overlapping lesion of colon (C18.8), and colon not otherwise specified (C18.9).
Analysis
We compared demographic and tumor factors by histological subtype (mucinous, nonmucinous, and signet-ring cell) by χ 2 test. Cancer-specific death was compared in univariate analysis with the log-rank test, and multivariate Cox regression analyses compared cancer-specific death for the 3 histological subtypes while controlling for patients' age (<50 years, 50-75 years, >75 years), sex, race (white, black, other), tumor grade (well, moderately, poorly, undifferentiated, and unknown), total number of lymph nodes evaluated (0, ≥1, unknown), year of diagnosis (1988-1991, 1992-1995, 1996-1999, 2000-2003, 2004-2007) , and surgery received (no surgery/local tumor destruction/local excision/unknown, appendectomy, hemicolectomy, total colectomy/proctocolectomy). Within SEER, an appendectomy is not specifically recorded and is defined in this report as representing the SEER surgical code of partial colec-tomy less than hemicolectomy. Models were built separately for stages I to III disease and stage IV disease.
The SEER registry does not have a specific category for appendiceal cancer deaths, which are therefore classified as colorectal cancer. These codes yielded a total of 786 deaths, representing 81.8% of all defined cancer-specific deaths for CSS calculation. In addition, the distribution of the cause-of-death coding was evaluated to determine other relevant cancer-specific causes of death, and this identified a total of 174 cancer-specific deaths, accounting for the remaining 18.2% of all predefined cancer-specific deaths (Supplementary Table 1 , available at http://links.lww.com/SLA/A285). Cases were censored if death was from a cause other than those specified above or if the patient was alive at the last follow-up. To account for the possible unreliable cause-of-death information in SEER, we exclusively used multivariate relative survival regression modeling with the Poisson assumption for the observed number of deaths to confirm our findings. 14 Within population-based data, appendiceal cancer is associated with a significant proportion of patients with missing data regarding tumor grade. To address the impact of missing histological grade on survival, we performed 3 separate analyses that alternatively excluded all cases of unknown histological grade, included all cases of unknown grade as a separate grade category, and included all cases of unknown grade by multiple imputation. 15 Specifically, for the multiple imputation method, we replaced the missing grade with distributions of plausible values that accounted for the uncertainty about the imputed value. The missing values were imputed with 100 sets of plausible values based on the Bayesian posterior predictive distribution derived from the imputation model adjusted for age, sex, race, stage, number of total lymph nodes evaluated, year of diagnosis, surgery received, time to cancer-specific death, and death indicator. The imputation models were built separately by stage (stages I-III or stage IV) and histological subtype (mucinous or nonmucinous).
Statistical analyses were performed using Stata SE version 11.0 (released 2010, College Station, TX). Because the study used preexisting data with no personal identifiers, this study was exempt from review by our institutional review board.
RESULTS
Clinicopathological Characteristics
A total of 2469 patients with appendiceal carcinomas met the eligibility criteria. Baseline characteristics stratified by histological subtype are shown in Table 1 . The median age was 58 years (interquartile range: 48-70 years) and was similar between mucinous and signet-ring cell (Kruskal-Wallis test, P = 0.16) and significant between both nonmucinous and mucinous (P < 0.05) and nonmucinous and signet-ring cell (P < 0.05). Female sex was more common in mucinous (57%) and in signet-ring cell (62%) than in nonmucinous adenocarcinomas (45%). The overall stage distribution was 8% stage I, 22% stage II, 11% stage III, 41% stage IV, and 18% unstaged. The primary reason for being classified as unstaged was the lack of information regarding nodal status (Nx, 97% of unstaged cases). Stage distribution varied by histological subtype (P < 0.001), with stage IV disease being more common in mucinous and signet-ring cell adenocarcinomas (48% and 59%, respectively) than in nonmucinous adenocarcinomas (25%). Stage III disease was uncommon for the mucinous histological subtype, representing only 6% of cases, and this finding was more pronounced for the well-differentiated mucinous adenocarcinomas, with only 9 cases (1.2%).
The histological grade was well differentiated in 22% of patients, moderately differentiated in 30%, poorly differentiated in 18%, and not otherwise specified in 29%. The rate of the unspecified histological grade for mucinous, signet-ring cell, and nonmucinous histological subtypes was 35%, 38%, and 17%, respectively. For mucinous and nonmucinous histological subtypes, the cases with missing histological grade were most commonly those identified as stage IV disease, 53% and 46%, or unknown stage, 22% and 24%, respectively. Well-differentiated adenocarcinomas were more frequently seen with the mucinous histological subtype (31%) than with the signet-ring cell (1%) and nonmucinous (14%) subtypes (P < 0.001).
The type of surgical resection for stage unknown, I, II, or III disease was an appendectomy in 30%, hemicolectomy in 41%, total colectomy/proctocolectomy in 14%, and local resection/local tumor destruction/no surgery/unknown surgery in 15%. In the 458 cases with locoregional disease that underwent an appendectomy, 46%, 36%, and 18% had unknown nodal evaluation (Nx), 1 to 12 lymph nodes evaluated, and more than 12 lymph nodes evaluated in the pathological specimen, respectively.
Cancer-Specific Survival
CSS rates stratified by histological subtype, stage, and grade are shown in Figure 1 . Mucinous and nonmucinous adenocarcinomas demonstrated similar 5-year CSS rates of 56% (mucinous) and 54% (nonmucinous), respectively, whereas signet-ring cell carcinomas had a worse outcome (22%, Fig. 1A) . Surprisingly, stage-stratified CSS demonstrated similar outcomes for stage III and stage IV disease (Fig. 1B) . However, this finding was confounded by the histological subtype, as stage III cases were more commonly nonmucinous (52%) versus mucinous (32%, P < 0.001) and stage IV cases were more commonly mucinous (65%) versus nonmucinous (21%, P < 0.001).
In comparison with histological subtype-or stage-stratified CSS, histological grade-stratified CSS seems to provide the best discrimination of CSS (Fig. 1C) . However, grade-stratified CSS was also influenced by the histological subtype with mucinous adenocarcinomas being most commonly well (31%) or moderately (24%) differentiated, whereas nonmucinous adenocarcinomas were moderately (47%) or poorly (22%) differentiated and signet-ring cell adenocarcinomas were poorly differentiated (52%, Table 1 ).
Stage-stratified CSS rates for both mucinous and nonmucinous histological subtypes (excluding signet-ring cell histological subtype and cases with undifferentiated grade) are shown in Figure 2 . Though CSS rates were similar for stages I to III disease, the CSS rates for stage IV disease differed dramatically between histological subtypes.
Stage-and Grade-Stratified CSS
Because of the strong prognostic impact of both histological grade and stage, in addition to the interplay between these factors, grade-and stage-stratified CSS were analyzed for both mucinous and nonmucinous adenocarcinomas. The impact of the histological grade upon CSS for stage I to III mucinous and nonmucinous carcinomas was similar (Figs. 3A, C) . The 5-year CSS rates for stage I to III well-differentiated, moderately differentiated, and poorly differentiated mucinous adenocarcinomas were 82%, 64%, and 50%, respectively, whereas for nonmucinous adenocarcinomas, the 5-year CSS rates were 69%, 73%, and 55%.
For stage IV mucinous and nonmucinous adenocarcinomas, the histological grade had a differential impact, with well-, moderately, and poorly differentiated mucinous adenocarcinomas having distinctly different CSS, whereas CSS for moderately and poorly differentiated nonmucinous adenocarcinomas were similar (Figs. 3B,  D) . Well-differentiated stage IV nonmucinous adenocarcinomas represented a small subset with only 17 cases. Five-year CSS rates stratified by well, moderate, or poor tumor grade were 71%, 51%, and 0%, respectively, for mucinous adenocarcinomas and 48%, 9%, and 5% for nonmucinous adenocarcinomas, respectively.
Multivariate Analysis
To further evaluate the impact of grade and stage on mucinous and nonmucinous appendiceal adenocarcinomas, a multivariate model utilizing unknown grade as a separate grade category was constructed and hazard ratios are shown in Table 2 . To confirm these findings, we also analyzed the histological grade in our multivariate model after multiple imputation or after exclusion ( Table 2 ). With all 3 methods, our results remained unchanged. In addition, we also performed multivariate relative survival regression analysis and confirmed these findings (Supplementary Table 2 , available at http:// links.lww.com/SLA/A285).
Histological grade was a stronger prognostic factor for mucinous than for nonmucinous appendiceal adenocarcinomas. This was most dramatically seen with stage IV mucinous adenocarcinoma where the CSS hazard ratios for moderately differentiated and poorly differentiated histological grade were 1.56 [95% confidence interval (CI): 1.08-2.25] and 5.15 (95% CI: 3.45-7.68), in comparison with 1.73 (95% CI: 0.83-3.6) and 1.93 (95% CI: 0.94-3.97) for nonmucinous adenocarcinomas, respectively.
To better understand the relative impact of grade in mucinous and nonmucinous appendiceal adenocarcinomas, we performed the same analysis for adenocarcinomas of the colon (Supplementary Table 3 , available at http://links.lww.com/SLA/A285). The impact of the grade for colon adenocarcinomas was similar between mucinous and nonmucinous histological subtypes with poorly differentiated mucinous and nonmucinous having CSS hazard ratios of 1.66 (95% CI: 1.56-1.77) and 1.64 (95% CI: 1.42-1.88), respectively, for stages I to III, and 1.71 (95% CI: 1.6-1.84) and 1.82 (95% CI: 1.54-2.15), respectively, for stage IV.
DISCUSSION
This analysis highlights the interplay between the histological type (mucinous or nonmucinous), stage, and grade for patients with appendiceal adenocarcinoma. The analysis also shows that the relationships among these factors are empirically not independent. The prognostic implication of the histological grade is greater for mucinous than for nonmucinous appendiceal adenocarcinomas. Notably, this impact is primarily due to the improved outcome of moderately and well-differentiated stage IV mucinous but not nonmucinous appendiceal adenocarcinomas. Furthermore, within each stage, poorly differentiated appendiceal adenocarcinomas are associated with poor outcomes irrespective of histological subtype. Finally, the distinctly different outcomes for moderately as opposed to poorly differentiated mucinous appendiceal adenocarcinomas suggest that these 2 histological grades should not be combined into a single high-grade mucinous category, as is currently recommended in the AJCC Staging Manual 7th edition. Consistent with previous reports, we identified a number of differences between mucinous and nonmucinous appendiceal adenocarcinomas, with female sex, stage IV disease, and well-differentiated histology being more common for mucinous adenocarcinomas. 1, 16 Interestingly, mucinous adenocarcinomas are more than 2 times more likely to present with stage IV disease as nonmucinous adenocarcinomas (48% vs 25%, respectively). Yet, stage III disease at presentation was extremely rare for mucinous adenocarcinomas (6%), and this was even more evident for well-differentiated mucinous adenocarcinomas (1.2%), suggesting a strong propensity for peritoneal rather than lymphatic metastases. From the data presented here, the apparent similarity in overall CSS for mucinous and nonmucinous appendiceal adenocarcinomas likely does not reflect similar disease biology, but rather the higher rate of localized disease for nonmucinous adenocarcinomas than for mucinous adenocarcinomas and the improved CSS for stage IV mucinous adenocarcinomas compared with stage IV nonmucinous adenocarcinomas. Little is known about appendiceal adenocarcinomas at the molecular level and only 1 prior study has directly compared the molecular patterns of mucinous and nonmucinous histological subtypes, observing similar rates of K-ras mutations, microsatellite instability, and p53 overexpression. 5 A notable finding from these data was the stage-dependent impact of the grade on survival for patients with mucinous adenocarcinomas. Although poor differentiation was associated with worse outcome in all stages, the magnitude of this impact was very stagedependent as reflected by adjusted hazard ratios (compared with well-differentiated) of 1.90 and 4.94 for stages I to III and stage IV, respectively. This finding was not seen for nonmucinous appendiceal adenocarcinomas where the impact of the histological grade on survival was stage-independent. To better understand the impact of mucinous histology and grade in appendiceal adenocarcinomas, we performed the same analysis in colon adenocarcinomas. The impact of the grade on survival outcomes of colon adenocarcinomas was independent of stage and mucinous histology. In fact, the prognostic impact of grade in colon adenocarcinomas seems similar to that seen for nonmucinous adenocarcinomas of the appendix. These findings further support the unique biological behavior of mucinous adenocarcinomas of the appendix.
In the 7th edition of the AJCC Staging Manual, appendiceal carcinomas are classified separately from colorectal carcinomas with (1) a distinction made between mucinous and nonmucinous histological subtypes, (2) classification of the histological grade for mucinous carcinomas as either low or high, and (3) substratification of metastases into intraperitoneal and extraperitoneal categories. 11 As the SEER registry does not provide information on the sites of metastatic disease, we were not able to evaluate the impact of metastatic sites on outcomes. However, prior data for appendiceal adenocarcinomas have suggested a low rate of extraperitoneal dissemination. 17, 18 This analysis has confirmed the unique clinical behaviors of mucinous versus nonmucinous subtypes and supports their distinction. However, the merging of moderately and poorly differentiated grades into a single high-grade category is not supported by our data. In patients with stage IV mucinous adenocarcinomas, statistically significant differences in CSS were demonstrated for moderate and poor differentiation. No statistically significant difference was seen for stage I to III mucinous adenocarcinomas, though this analysis was limited by sample size.
A potential limitation of this analysis relates to the high rate of cases with an unknown histological grade. As the histological classification of mucinous appendiceal neoplasm represents a diagnostic challenge, a number of classification systems exist. 12, [19] [20] [21] It is possible that some cases of unknown grade may reflect the use of alternative grading systems using such terms as peritoneal mucinous carcinomatosis (PMCA)-1 or PMCA-2 as proposed by Ronnett et al, or mucinous carcinoma peritonei low grade or high grade as proposed by Bradley et al. 12, 19 In either instance, such histological grading would be recorded in SEER under the category of unknown grade. To evaluate the impact of a missing histological grade, we utilized 3 separate techniques for handling missing data and constructed separate multivariate logistic regression models examining missing histological grade as an included, excluded, or imputed data. 15 In strong support of our findings, we found consistent findings across all 3 models. An additional area of confusion regarding the histological classification of mucinous appendiceal neoplasms relates to cases in which microscopic evaluation of the appendix reveals a neoplasm with bland or low-grade cytological features, which lacks the architectural abnormalities characteristic of invasive carcinoma (ie, destructive invasion with associated desmoplasia), yet there is intraperitoneal dissemination of abundant mucinous material containing neoplastic cells with bland or low-grade dysplastic features. In one of the most common classification systems, these neoplasms have been termed disseminated peritoneal adenomucinosis. 19 As SEER does not capture data on cases with histologically benign or uncertain malignant potential, this subgroup of neoplasms is not represented in this analysis.
As in other malignancies, including colorectal cancer, the distinction between well-, moderately, and poorly differentiated carcinomas represents a subjective assessment with interobserver variation. 22, 23 However, despite this limitation, the histological grade has consistently been identified as a statistically significant independent marker of colorectal cancer prognosis. [24] [25] [26] Though it is likely that subjectivity in the histological grading of moderately and poorly differentiated mucinous adenocarcinomas exists, our data show that this distinction, as determined by a multitude of pathologists across the SEER reporting sites, is prognostically relevant.
As with most registry-based observational studies, there are both strengths and limitations to our analysis. First, there are clinical variables that are not included within the SEER registry, which may affect a comparison of outcomes including comorbidities, pathological margin status, use of systemic chemotherapy, and the receipt of cytoreductive surgery with or without intraperitoneal chemotherapy for carcinomatosis. As the decisions for cytoreductive surgery and systemic chemotherapy are subject to influence by the histological grade and histological subtype (ie, poorly differentiated or nonmucinous cancers with carcinomatosis are generally not treated with cytoreductive surgery), the biological rationale for these treatment decisions only supports our observations regarding the importance of grade and histology for stage IV disease, particularly with respect to the merging of moderately and poorly differentiated mucinous adenocarcinomas into a single high-grade category. Second, there were a number of incompletely staged cases that could potentially skew the data. The primary reason for lacking stage assignment was missing information regarding nodal status and the proportion of unstaged patients was similar among the histological subtypes. Finally, within SEER, surgical resection for appendiceal adenocarcinomas is imperfectly classified, as both appendectomy and cecectomy are recorded as a partial colectomy. In addition, it is possible that a number of unstaged cases were treated by an appendectomy alone, as these cases could represent cases with localized disease that did not have nodal staging information. Though the exact rate of cases treated with an appendectomy cannot be determined, similar rates of partial colectomy and unstaged cases were seen between mucinous and nonmucinous histological subtypes, suggesting that this was not a significant limitation to our analysis. Despite these limitations, the large sample size of nearly 2000 patients and the ability to perform stratified adjusted survival analysis to account for the interplay between the clinically important prognostic variables, is an important advantage of the SEER registry.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
